20 articles
Losing a key cholinergic peptide dramatically worsens memory in Alzheimer's mice, pointing to a overlooked pathway in cognitive decline.
New peptide delivery system restores brain connections and memory function in Alzheimer's models, offering hope for treating cognitive decline.
Analysis of 177 cases with E200K mutation identifies new disease patterns that could improve diagnosis and understanding.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
New review reveals how engineered peptides could revolutionize Alzheimer's therapy by targeting multiple disease pathways simultaneously.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Researchers decoded how ketamine fights depression via opioid receptors, revealing a roadmap to safer, more targeted antidepressants.
Scientists discover blocking UCHL3 enzyme reduces toxic protein clumps and improves cellular cleanup in Huntington's disease models.
A novel Aฮฒ1-10 peptide vaccine conjugated to carrier proteins reduced plaques, neuroinflammation, and memory deficits in an AD mouse model.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A deep mechanistic exploration of how hypothalamic IKKฮฒ/NF-ฮบB signaling, htNSC exosomal communication, and multi-axis hormonal dysregulation drive systemic aging โ plus cutting-edge therapeutic strategies.
ฮฒ-endorphin released during exercise wraps around toxic Aฮฒ aggregates, forming a 'corona' that shields brain cells from Alzheimer's damage.
Dr. Kyle Gillett reveals evidence-based strategies to optimize hormones naturally through lifestyle interventions for men and women.
Synthetic peptide chimeras degrade amyloid-beta across the blood-brain barrier, improving cognition in mice with fewer risks than current immunotherapies.
Review reveals how PQQ supplement protects neurons via antioxidant, mitochondrial, and anti-inflammatory mechanisms in neurodegenerative diseases.
Deleting or inhibiting astrocytic PERK restores the brain's glymphatic drainage system and dramatically reduces Aฮฒ and tau pathology in AD mouse models.
A Harvard-developed digital seed amplification assay can precisely quantify TDP-43 protein aggregates in CSF, offering a potential diagnostic breakthrough for frontotemporal dementia.
A 4-protein panel in neuronal extracellular vesicles outperforms standard plasma tests in flagging early Alzheimer's brain changes.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
New research reveals how GFAP protein actively shapes brain aging and could enable early detection of neurodegenerative diseases.
